Search

Your search keyword '"Heymach, John"' showing total 127 results
Start Over Author "Heymach, John" Publisher elsevier b.v.
127 results on '"Heymach, John"'

1. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer

Author

Park, Sehhoon, Hong, Tae Hee, Hwang, Soohyun, Heeke, Simon, Gay, Carl M., Kim, Jiyeon, Jung, Hyun-Ae, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Cho, Jong Ho, Choi, Yong Soo, Kim, Jhingook, Shim, Young Mog, Kim, Hong Kwan, Byers, Lauren Averett, Heymach, John V., Choi, Yoon-La, Lee, Se-Hoon, and Park, Keunchil

Published
2024
Full Text
View/download PDF

2. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma

Author

Corrigan, Kelsey L., Xu, Ting, Sasaki, Yuki, Lin, Ruitao, Chen, Aileen B., Welsh, James W., Lin, Steven H., Chang, Joe Y., Ning, Matthew S., Gandhi, Saumil, O'Reilly, Michael S., Gay, Carl M., Altan, Mehmet, Lu, Charles, Cascone, Tina, Koutroumpakis, Efstratios, Sheshadri, Ajay, Zhang, Xiaodong, Liao, Li, Zhu, X. Ronald, Heymach, John V., Nguyen, Quynh-Nhu, and Liao, Zhongxing

Published
2024
Full Text
View/download PDF

3. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide

Author

Liu, Stephen V., Mok, Tony S.K., Nabet, Barzin Y., Mansfield, Aaron S., De Boer, Richard, Losonczy, György, Sugawara, Shunichi, Dziadziuszko, Rafal, Krzakowski, Maciej, Smolin, Alexey, Hochmair, Maximilian J., Garassino, Marina C., Gay, Carl M., Heymach, John V., Byers, Lauren A., Lam, Sivuonthanh, Cardona, Andrés, Morris, Stefanie, Adler, Leah, Shames, David S., and Reck, Martin

Published
2023
Full Text
View/download PDF

5. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment

Author

Akhave, Neal, Zhang, Jiexin, Bayley, Erin, Frank, Meredith, Chiou, Shin-Heng, Behrens, Carmen, Chen, Runzhe, Hu, Xin, Parra, Edwin Roger, Lee, Won-Chul, Swisher, Stephen, Solis, Luisa, Weissferdt, Annikka, Moran, Cesar, Kalhor, Neda, Zhang, Jianhua, Scheet, Paul, Vaporciyan, Ara A., Sepesi, Boris, Gibbons, Don L., Heymach, John V., Lee, Jack J., Wistuba, Ignacio I., Andrew Futreal, P., Zhang, Jianjun, Fujimoto, Junya, and Reuben, Alexandre

Published
2022
Full Text
View/download PDF

6. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection

Author

Deboever, Nathaniel, McGrail, Daniel J., Lee, Younghee, Tran, Hai T., Mitchell, Kyle G., Antonoff, Mara B., Hofstetter, Wayne L., Mehran, Reza J., Rice, David C., Roth, Jack A., Swisher, Stephen G., Vaporciyan, Ara A., Walsh, Garrett L., Bernatchez, Chantale, Vailati Negrao, Marcelo, Zhang, Jianjun, Wistuba, Ignacio I., Heymach, John V., Cascone, Tina, Gibbons, Don L., Haymaker, Cara L., and Sepesi, Boris

Published
2022
Full Text
View/download PDF

7. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial

Author

Patel, Roshal R., He, Kewen, Barsoumian, Hampartsoum B., Chang, Joe Y., Tang, Chad, Verma, Vivek, Comeaux, Nathan, Chun, Stephen G., Gandhi, Saumil, Truong, Mylene T., Erasmus, Jeremy J., Hong, David S., Lee, Percy P., Ning, Matthew S., Nguyen, Quynh-Nhu, Heymach, John V., Altan, Mehmet, Blumenschein, George, Fossella, Frank V., Sezen, Duygu, Chen, Dawei, Carter, Brett W., Davies, Michael A., Glitza, Isabella C., Diab, Adi, Ferrarotto, Renata, Cabanillas, Maria E., Yuan, Ying, Shah, Shalin J., Parra, Edwin R., Sun, Baohua, Cortez, Maria Angelica, and Welsh, James W.

Published
2021
Full Text
View/download PDF

9. Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis.

Author

Soto-Lanza, Felipe, Glick, Lydia, Chan, Colin, Zhong, Linda, Wilson, Nathaniel, Faiz, Saadia, Gandhi, Saumil, Aung Naing, Heymach, John V., Shannon, Vickie R., Franco-Vega, Maria, Zhongxing Liao, Lin, Steven H., Palaskas, Nicolas L., Jia Wu, Shroff, Girish S., Altan, Mehmet, and Sheshadri, Ajay

Published
2024
Full Text
View/download PDF

13. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively

Author

Corsini, Erin M., Wang, Qi, Tran, Hai T., Mitchell, Kyle G., Antonoff, Mara B., Hofstetter, Wayne L., Mehran, Reza J., Rice, David C., Roth, Jack A., Swisher, Stephen G., Vaporciyan, Ara A., Walsh, Garrett L., Reuben, Alexandre, Vasquez, Mayra E., Bernatchez, Chantale, Wang, Jing, Cascone, Tina, Zhang, Jianjun, Heymach, John V., Gibbons, Don L., Haymaker, Cara L., and Sepesi, Boris

Published
2020
Full Text
View/download PDF

18. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer

Author

Hao, Chuncheng, Wang, Li, Peng, Shaohua, Cao, Mengru, Li, Hongyu, Hu, Jing, Huang, Xiao, Liu, Wei, Zhang, Hui, Wu, Shuhong, Pataer, Apar, Heymach, John V., Eterovic, Agda Karina, Zhang, Qingxiu, Shaw, Kenna R., Chen, Ken, Futreal, Andrew, Wang, Michael, Hofstetter, Wayne, Mehran, Reza, Rice, David, Roth, Jack A., Sepesi, Boris, Swisher, Stephen G., Vaporciyan, Ara, Walsh, Garrett L., Johnson, Faye M., and Fang, Bingliang

Published
2015
Full Text
View/download PDF

22. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer.

Author

Sepesi, Boris, Zhou, Nicolas, William, William N., Lin, Heather Y., Leung, Cheuk H., Weissferdt, Annikka, Mitchell, Kyle G., Pataer, Apar, Walsh, Garrett L., Rice, David C., Roth, Jack A., Mehran, Reza J., Hofstetter, Wayne L., Antonoff, Mara B., Rajaram, Ravi, Negrao, Marcelo V., Tsao, Anne S., Gibbons, Don L., Lee, J. Jack, and Heymach, John V.

Abstract

Surgical outcomes for non–small cell lung cancer after neoadjuvant immune checkpoint inhibitors continue to be debated. We assessed perioperative outcomes of patients treated with Nivolumab or Nivolumab plus Ipilimumab (NEOSTAR) and compared them with patients treated with chemotherapy or previously untreated patients with stage I-IIIA non–small cell lung cancer. Forty-four patients with stage I to IIIA non–small cell lung cancer (American Joint Committee on Cancer Staging Manual , seventh edition) were randomized to nivolumab (N; 3 mg/kg intravenously on days 1, 15, and 29; n = 23) or nivolumab with ipilimumab (NI; I, 1 mg/kg intravenously on day 1; n = 21). Curative-intent operations were planned between 3 and 6 weeks after the last dose of neoadjuvant N. Patients who completed resection upfront or after chemotherapy from the same time period were used as comparison. In the N arm, 21 (91%) were resected on-trial, 1 underwent surgery off-trial, and one was not resected (toxicity-related). In the NI arm, 16 (76%) resections were performed on-trial, one off-trial, and 4 were not resected (none toxicity-related). Median time to operation was 31 days, and consisted of 2 (5%) pneumonectomies, 33 (89%) lobectomies, and 1 (3%) each of segmentectomy and wedge resection. The approach was 27 (73%) thoracotomy, 7 (19%) thoracoscopy, and 3 (8%) robotic-assisted. Conversion occurred in 17% (n = 2/12) of minimally invasive cases. All 37 achieved R0 resection. Pulmonary, cardiac, enteric, neurologic, and wound complications occurred in 9 (24%), 4 (11%), 2 (5%), 1 (3%), and 1 (3%) patient, respectively. The 30- and 90-day mortality rate was 0% and 2.7% (n = 1), respectively. Postoperative complication rates were comparable with lung resection upfront or after chemotherapy. Operating after neoadjuvant N or NI is overall safe and effective and yields perioperative outcomes similar to those achieved after chemotherapy or upfront resection. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. A STING operation to expose KRAS and STK11 co-mutated lung cancers.

Author

Skoulidis, Ferdinandos, Heymach, John V., and Cascone, Tina

Subjects
*UNDERCOVER operations, *LUNG cancer, *NON-small-cell lung carcinoma, *NATURAL immunity
Abstract

KRAS and STK11 (LKB1) co-mutated (KL) tumors define an immunologically cold and anti-PD-(L)1-refractory non-small-cell lung cancer (NSCLC) subset. In this issue of Cancer Cell , Kitajima et al. outline a strategy to unleash innate immunity in KL tumors by utilizing epigenetic de-repression of STING and pulsed inhibition of spindle assembly checkpoint kinase MPS1. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non–small cell lung cancer: Evidence for surgery in advanced disease.

Author

Deboever, Nathaniel, Mitchell, Kyle G., Farooqi, Ahsan, Ludmir, Ethan B., Hofstetter, Wayne L., Mehran, Reza J., Rajaram, Ravi, Rice, David C., Sepesi, Boris, Swisher, Stephen G., Vaporciyan, Ara A., Walsh, Garrett L., Heymach, John V., Gomez, Daniel R., Gandhi, Saumil J., and Antonoff, Mara B.

Abstract

Recent randomized trials have demonstrated a survival advantage with the use of local consolidative therapy in oligometastatic non–small cell lung cancer; however, the indications for and outcomes after pulmonary resection as a component of local consolidative therapy remain ill defined. We sought to characterize the perioperative and long-term survival outcomes among patients with resected oligometastatic non–small cell lung cancer. Patients presenting to a single center (2000-2017) with oligometastatic non–small cell lung cancer (≤3 synchronous metastases, intrathoracic nodal disease counted as a single site) who underwent resection of the primary tumor were retrospectively identified. Charts were reviewed, and demographic, clinical, pathologic, oncologic, and survival outcomes were recorded. Survival outcomes were analyzed from the date of surgery. A total of 52 patients met inclusion criteria, among whom most (38, 73.1%) were ever smokers, had nonsquamous tumors (48, 92.3%), had no intrathoracic nodal disease (33, 63.5%), and had 1 to 2 sites of metastases (49, 94.2%). The majority (41, 78.9%) received systemic therapy, predominantly in the neoadjuvant setting (24/41, 58.5%). After resection, there were no 30- or 90-day deaths. After a median follow-up of 94.6 months (95% CI, 69.0-139.1), 37 patients (71.2%) progressed and 38 patients (73.1%) died. Median postoperative progression-free survival and overall survival were 9.4 (5.5-11.6) months and 51.7 (22.3-65.3) months, respectively. Pulmonary resection as a means of maximum locoregional control in oligometastatic non–small cell lung cancer is feasible and safe, and may be associated with durable long-term survival benefits. The frequency of systemic postoperative progression highlights an urgent need to characterize perioperative and oncologic outcomes after pulmonary resection in the current era of novel systemic therapies. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.

Author

Negrao, Marcelo V., Raymond, Victoria M., Lanman, Richard B., Robichaux, Jacqulyne P., He, Junqin, Nilsson, Monique B., Ng, Patrick K.S., Amador, Bianca E., Roarty, Emily B., Nagy, Rebecca J., Banks, Kimberly C., Zhu, Viola W., Ng, Chun, Chae, Young Kwang, Clarke, Jeffrey M., Crawford, Jeffrey A., Meric-Bernstam, Funda, Ignatius Ou, Sai-Hong, Gandara, David R., and Heymach, John V.

Published
2020
Full Text
View/download PDF

37. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.

Author

Travis, William D., Dacic, Sanja, Wistuba, Ignacio, Sholl, Lynette, Adusumilli, Prasad, Bubendorf, Lukas, Bunn, Paul, Cascone, Tina, Chaft, Jamie, Chen, Gang, Chou, Teh-Ying, Cooper, Wendy, Erasmus, Jeremy J., Ferreira, Carlos Gil, Goo, Jin-Mo, Heymach, John, Hirsch, Fred R., Horinouchi, Hidehito, Kerr, Keith, and Kris, Mark

Published
2020
Full Text
View/download PDF

38. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancer.

Author

Feldman, Hope, Sepesi, Boris, Leung, Cheuk H., Lin, Heather, Weissferdt, Annikka, Pataer, Apar, William, William N., Walsh, Garrett L., Rice, David C., Roth, Jack A., Mehran, Reza J., Hofstetter, Wayne L., Antonoff, Mara B., Rajaram, Ravi, Gibbons, Don L., Lee, J. Jack, Heymach, John V., Vaporciyan, Ara A., Swisher, Stephen G., and Cascone, Tina

Abstract

Chemotherapy plus nivolumab is the standard of care neoadjuvant treatment for patients with resectable stage IB to IIIA non–small cell lung cancer. The influence of dual checkpoint blockade with chemotherapy on surgical outcomes remains unknown. We aimed to determine operative complexity and perioperative outcomes associated with neoadjuvant chemotherapy and nivolumab with or without ipilimumab. A total of 44 patients with stage IB (≥4 cm) to IIIA non–small cell lung cancer were treated on sequential platform arms of the NEOSTAR trial. A total of 22 patients were treated with nivolumab + chemotherapy, and 22 patients were treated with ipilimumab + nivolumab + chemotherapy. The safety of surgical resection after neoadjuvant therapy was estimated using 30-day complication rates. Operative reports and surgeons' narratives were evaluated to determine procedural complexity and operative conduct. All 22 of 22 patients (100%) treated with nivolumab + chemotherapy underwent surgical resection: 20 R0 (90.9%), 17 (77.3%) lobectomies, 1 wedge resection, 2 segmentectomies, and 2 pneumonectomies. The majority, 21 of 22 (95%), were performed by thoracotomy. A total of 13 of 22 (59.1%) were rated as challenging resections. A total of 4 of 22 patients (18.2%) experienced grade 3 or greater Clavien-Dindo complication. A total of 20 of 22 patients (90.9%) treated with ipilimumab + nivolumab + chemotherapy underwent surgical resection: 19 R0 (95%), 18 (90%) lobectomies, 1 pneumonectomy, and 1 segmentectomy. A total of 16 of 20 (80%) resections were performed via thoracotomy, 3 of 20 (15%) via robotics, and 1 of 20 (5%) via thoracoscopy. A total of 9 of 20 (45%) resections were considered challenging. A total of 4 of 20 patients (20%) experienced grade 3 or greater Clavien-Dindo complication. Surgical resections are feasible and safe, with high rates of R0 after neoadjuvant chemotherapy and nivolumab with or without ipilimumab. Overall, approximately half of cases (22/42, 52.3%) were considered to be more challenging than a standard lobectomy. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.

Author

Mitchell, Kyle G., Negrao, Marcelo V., Parra, Edwin R., Li, Jun, Zhang, Jianhua, Dejima, Hitoshi, Vaporciyan, Ara A., Swisher, Stephen G., Weissferdt, Annikka, Antonoff, Mara B., Cascone, Tina, Roarty, Emily, Wistuba, Ignacio I., Heymach, John V., Gibbons, Don L., Zhang, Jianjun, and Sepesi, Boris

Abstract

High tumor mutational burden (TMB) and programmed death ligand 1 (PD-L1) expression are leading biomarkers in metastatic non-small cell lung cancer (NSCLC) and predict favorable response to checkpoint inhibitors. We sought to identify clinicopathologic characteristics associated with elevated TMB and PD-L1 expression among patients who underwent resection for NSCLC. NSCLC patients undergoing primary resection (2016-2018) were prospectively enrolled in an immunogenomic profiling project. Multiplex immunofluorescence quantified densities (cells/mm2) of CD3+, CD3+CD8+, CD3+CD8+PD-1+, malignant cells (MCs), MCsPD-L1+, CD68+, CD68+PD-L1+, and CD20+ cells. Whole-exome sequencing quantified TMB (mutations/megabase). TMB and MCsPD-L1+ were dichotomized according to the median of each. A total of 55 patients completed multiplex immunofluorescence and whole-exome sequencing profiling. In this sample, 41.8% (23 of 55) had pathologic stage I disease. Median TMB and MCsPD-L1+ were 3.91 and 0.62 cells/mm2, respectively. TMB was higher among smokers (P =.001) and tumors with lymphovascular invasion (LVI) (P =.051). TMB was positively correlated with densities of MCsPD-L1+ (r = 0.293, P =.030), CD68+PD-L1+ (r = 0.289, P =.033), and CD20+ (r = 0.310, P =.043) cells. The density of MCsPD-L1+ was associated with increased CD3+CD8+ (r = 0.319, P =.018) and CD68+PD-L1+ (r = 0.371, P =.005) cells. Patients with PD-L1HighTMBHigh tumors (30.9%, 17 of 55) had higher intratumoral densities of CD3+, CD3+CD8+, CD68+, CD68+PD-L1+, and CD20+ cells. On multivariable analysis LVI was associated with synchronous elevated TMB and PD-L1 expression (odds ratio 3.53, P =.039). NSCLC tumors with elevated TMB and PD-L1 expression are associated with LVI and increased intratumoral immune cell infiltration. These findings may potentially improve patient selection for checkpoint inhibitor therapy trials in the adjuvant setting. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

40. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.

Author

Welsh, James W., Heymach, John V., Chen, Dawei, Verma, Vivek, Cushman, Taylor R., Hess, Kenneth R., Shroff, Girish, Tang, Chad, Skoulidis, Ferdinandos, Jeter, Melenda, Menon, Hari, Nguyen, Quynh-Nhu, Chang, Joe Y., Altan, Mehmet, Papadimitrakopoulou, Vassiliki A., Simon, George R., Raju, Uma, Byers, Lauren, and Glisson, Bonnie

Published
2020
Full Text
View/download PDF

41. Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.

Author

Sen, Triparna, Della Corte, Carminia M., Milutinovic, Snezana, Cardnell, Robert J., Diao, Lixia, Ramkumar, Kavya, Gay, Carl M., Stewart, C. Allison, Fan, Youhong, Shen, Li, Hansen, Ryan J., Strouse, Bryan, Hedrick, Michael P., Hassig, Christian A., Heymach, John V., Wang, Jing, and Byers, Lauren A.

Published
2019
Full Text
View/download PDF

43. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.

Author

Negrao, Marcelo V., Lam, Vincent K., Reuben, Alexandre, Rubin, Maria Laura, Landry, Lara Lacerda, Roarty, Emily B., Rinsurongkawong, Waree, Lewis, Jeff, Roth, Jack A., Swisher, Stephen G., Gibbons, Don L., Wistuba, Ignacio I., Papadimitrakopoulou, Vassiliki, Glisson, Bonnie S., Blumenschein, George R., Lee, J. Jack, Heymach, John V., Zhang, Jianjun, and Blumenschein, George R Jr

Published
2019
Full Text
View/download PDF

44. Corrigendum to “Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials” [Lung Cancer 120 (June) (2018) 137–141]

Author

Maymani, Hossein, Hess, Kenneth, Groisberg, Roman, Hong, David S., Naing, Aung, Piha-Paul, Sarina, Janku, Filip, Fu, Siqing, Tsimberidou, Apostolia M., Pant, Shubham, Karp, Daniel, Liu, Shuang, Sun, Ming, Heymach, John, Simon, George, Meric-Bernstam, Funda, and Subbiah, Vivek

Published
2019
Full Text
View/download PDF

45. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).

Author

Elamin, Yasir Y., Gomez, Daniel R., Antonoff, Mara B., Robichaux, Jacqulyne P., Tran, Hai, Shorter, Melissa K., Bohac, Jadi M., Negrao, Marcelo Vailati, Le, Xiuning, Rinsurogkawong, Waree, Lewis, Jeff, Lacerda, Lara, Roarty, Emily B., Swisher, Stephen G., Roth, Jack A., Zhang, Jianjun, Papadimitrakopoulou, Vassiliki, and Heymach, John V.

Published
2019
Full Text
View/download PDF

46. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.

Author

Sepesi, Boris, Nelson, David B., Mitchell, Kyle G., Gibbons, Don L., Heymach, John V., Vaporciyan, Ara A., Swisher, Stephen G., and Roszik, Jason

Abstract

Background Immune checkpoint inhibitors that target the programmed cell death protein ligand 1 (PD-L1) pathway have shown benefit for the treatment of metastatic non-small cell lung cancer (NSCLC). However, the prognostic value of PD-L1 independent of immunotherapy is still unclear, with conflicting results reported between PD-L1 expression and patient survival. Our aim was to correlate PD-L1 mRNA level with clinical and pathologic factors and to investigative the prognostic value of PD-L1 mRNA in all stages of NSCLC. Methods Gene expression and clinical data were obtained from public repositories in The Cancer Genome Atlas from the National Cancer Institute. Genotype-Tissue Expression was used to compare with normal tissue expression analysis. Results A total of 985 patients met inclusion criteria, among whom 79.6% were stage I to II, 16.5% were stage III, and 3.5% were stage IV, representing 495 adenocarcinoma and 490 squamous cell carcinoma (SCC). PD-L1 mRNA gene expression in lung cancers was higher than in most other tumor and normal tissue types and was significantly higher in lung SCC than adenocarcinoma ( p < 0.001). PD-L1 mRNA expression was associated with pathologic stage in SCC and with smoking status in adenocarcinoma of the lung. However, none of the cutoff values of PD-L1 mRNA expression were prognostic of overall survival. Conclusions Our results suggest that the value of PD-L1 mRNA in prognosticating outcome in lung cancer is limited. Further studies are needed to identify novel prognostic biomarkers other than PD-L1 that are associated with improved patient survival. Identification of further prognostically important biomarkers may prove useful in identifying patients suitable for immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

47. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.

Author

Lee, Won-Chul, Diao, Lixia, Wang, Jing, Zhang, Jianhua, Roarty, Emily B., Varghese, Susan, Chow, Chi-Wan, Fujimoto, Junya, Behrens, Carmen, Cascone, Tina, Peng, Weiyi, Kalhor, Neda, Moran, Cesar A., Weissferdt, Annikka, Johnson, Faye M., William, William N., Swisher, Stephen G., Lee, J. Jack, Hong, Waun Ki, and Heymach, John V.

Published
2018
Full Text
View/download PDF

48. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.

Author

Parra, Edwin Roger, Villalobos, Pamela, Zhang, Jiexin, Behrens, Carmen, Mino, Barbara, Swisher, Stephen, Sepesi, Boris, Weissferdt, Annika, Kalhor, Neda, Heymach, John Victor, Moran, Cesar, Zhang, Jianjun, Lee, Jack, Rodriguez-Canales, Jaime, Gibbons, Don, Wistuba, Ignacio I., and Wistuba, Ignacio Ivan

Published
2018
Full Text
View/download PDF

49. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.

Author

Cascone, Tina, Gold, Kathryn A., Swisher, Stephen G., Liu, Diane D., Fossella, Frank V., Sepesi, Boris, Pataer, Apar, Weissferdt, Annikka, Kalhor, Neda, Vaporciyan, Ara A., Hofstetter, Wayne L., Wistuba, Ignacio I., Heymach, John V., Kim, Edward S., and Jr.William, William N.

Abstract

Background Data from meta-analyses support the use of induction or adjuvant platinum-based chemotherapy for locally advanced non-small cell lung cancers (NSCLCs). This phase 2 study assessed the role of induction cisplatin and docetaxel followed by surgery in patients with resectable stage I to III NSCLCs, followed by 12 months of adjuvant erlotinib. Methods Patients with resectable stage I to III NSCLCs received cisplatin 80 mg/m 2 , docetaxel 75 mg/m 2 every 21 days for 3 cycles, followed by surgery, followed by adjuvant erlotinib for 12 months. The primary endpoint included safety. Long-term efficacy outcomes and exploratory analysis of intermediary endpoints are also reported ( NCT00254384 ). Results Forty-seven eligible patients received a median of 3 cycles of induction treatment, 37 underwent surgical resection, and only 21 received adjuvant erlotinib. Two patients died in the perioperative period (1 sepsis during chemotherapy, 1 acute respiratory distress syndrome postoperatively). Most common grade 3 to 5 toxicities during chemotherapy included hypokalemia (8%), infection (7%), and granulocytopenia (25%). During adjuvant erlotinib, 14% of patients experienced grade 2 rash. Median overall survival was 3.4 years. Major pathologic responses in the primary tumor were observed in 19% (7 of 37) of patients and correlated with improved long-term overall survival. Complete pathologic response in mediastinal/hilar nodes also correlated with superior survival. Conclusions Induction cisplatin and docetaxel was well tolerated. Adjuvant erlotinib did not improve outcomes compared with historical controls. Major pathologic response predicted for improved long-term survival and is a suitable intermediary endpoint for future phase 2 studies. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results